| __timestamp | Amphastar Pharmaceuticals, Inc. | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 9689000 |
| Thursday, January 1, 2015 | 46974000 | 10431000 |
| Friday, January 1, 2016 | 47298000 | 9618000 |
| Sunday, January 1, 2017 | 50918000 | 12348000 |
| Monday, January 1, 2018 | 58044000 | 28310241 |
| Tuesday, January 1, 2019 | 63109000 | 59336147 |
| Wednesday, January 1, 2020 | 65157000 | 159145941 |
| Friday, January 1, 2021 | 68920000 | 199800000 |
| Saturday, January 1, 2022 | 66592000 | 90225000 |
| Sunday, January 1, 2023 | 80393000 | 92538000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of MorphoSys AG and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Amphastar Pharmaceuticals saw a steady increase in SG&A expenses, peaking at approximately 80 million in 2023, marking a 99% rise from 2014. Meanwhile, MorphoSys AG experienced a more volatile trajectory, with expenses surging by over 900% from 2014 to 2021, before stabilizing around 92 million in 2023. This stark contrast highlights the diverse strategies employed by these companies in managing operational costs. As the pharmaceutical landscape continues to shift, understanding these financial dynamics offers valuable insights into the strategic priorities of industry leaders.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Insmed Incorporated and MorphoSys AG
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.